#Breast Cancer Drug

[jcmarchi]

Unlocking mRNA’s cancer-fighting potential

New Post has been published on https://thedigitalinsider.com/unlocking-mrnas-cancer-fighting-potential/

Unlocking mRNA’s cancer-fighting potential

What if training your immune system to attack cancer cells was as easy as training it to fight Covid-19? Many people believe the technology behind some Covid-19 vaccines, messenger RNA, holds great promise for stimulating immune responses to cancer.

But using messenger RNA, or mRNA, to get the immune system to mount a prolonged and aggressive attack on cancer cells — while leaving healthy cells alone — has been a major challenge.

The MIT spinout Strand Therapeutics is attempting to solve that problem with an advanced class of mRNA molecules that are designed to sense what type of cells they encounter in the body and to express therapeutic proteins only once they have entered diseased cells.

“It’s about finding ways to deal with the signal-to-noise ratio, the signal being expression in the target tissue and the noise being expression in the nontarget tissue,” Strand CEO Jacob Becraft PhD ’19 explains. “Our technology amplifies the signal to express more proteins for longer while at the same time effectively eliminating the mRNA’s off-target expression.”

Strand is set to begin its first clinical trial in April, which is testing a proprietary, self-replicating mRNA molecule’s ability to express immune signals directly from a tumor, eliciting the immune system to attack and kill the tumor cells directly. It’s also being tested as a possible improvement for existing treatments to a number of solid tumors.

As they work to commercialize its early innovations, Strand’s team is continuing to add capabilities to what it calls its “programmable medicines,” improving mRNA molecules’ ability to sense their environment and generate potent, targeted responses where they’re needed most.

“Self-replicating mRNA was the first thing that we pioneered when we were at MIT and in the first couple years at Strand,” Becraft says. “Now we’ve also moved into approaches like circular mRNAs, which allow each molecule of mRNA to express more of a protein for longer, potentially for weeks at a time. And the bigger our cell-type specific datasets become, the better we are at differentiating cell types, which makes these molecules so targeted we can have a higher level of safety at higher doses and create stronger treatments.”

Making mRNA smarter

Becraft got his first taste of MIT as an undergraduate at the University of Illinois when he secured a summer internship in the lab of MIT Institute Professor Bob Langer.

“That’s where I learned how lab research could be translated into spinout companies,” Becraft recalls.

The experience left enough of an impression on Becraft that he returned to MIT the next fall to earn his PhD, where he worked in the Synthetic Biology Center under professor of bioengineering and electrical engineering and computer science Ron Weiss. During that time, he collaborated with postdoc Tasuku Kitada to create genetic “switches” that could control protein expression in cells.

Becraft and Kitada realized their research could be the foundation of a company around 2017 and started spending time in the Martin Trust Center for MIT Entrepreneurship. They also received support from MIT Sandbox and eventually worked with the Technology Licensing Office to establish Strand’s early intellectual property.

“We started by asking, where is the highest unmet need that also allows us to prove out the thesis of this technology? And where will this approach have therapeutic relevance that is a quantum leap forward from what anyone else is doing?” Becraft says. “The first place we looked was oncology.”

People have been working on cancer immunotherapy, which turns a patient’s immune system against cancer cells, for decades. Scientists in the field have developed drugs that produce some remarkable results in patients with aggressive, late-stage cancers. But most next-generation cancer immunotherapies are based on recombinant (lab-made) proteins that are difficult to deliver to specific targets in the body and don’t remain active for long enough to consistently create a durable response.

More recently, companies like Moderna, whose founders also include MIT alumni, have pioneered the use of mRNAs to create proteins in cells. But to date, those mRNA molecules have not been able to change behavior based on the type of cells they enter, and don’t last for very long in the body.

“If you’re trying to engage the immune system with a tumor cell, the mRNA needs to be expressing from the tumor cell itself, and it needs to be expressing over a long period of time,” Becraft says. “Those challenges are hard to overcome with the first generation of mRNA technologies.”

Strand has developed what it calls the world’s first mRNA programming language that allows the company to specify the tissues its mRNAs express proteins in.

“We built a database that says, ‘Here are all of the different cells that the mRNA could be delivered to, and here are all of their microRNA signatures,’ and then we use computational tools and machine learning to differentiate the cells,” Becraft explains. “For instance, I need to make sure that the messenger RNA turns off when it’s in the liver cell, and I need to make sure that it turns on when it’s in a tumor cell or a T-cell.”

Strand also uses techniques like mRNA self-replication to create more durable protein expression and immune responses.

“The first versions of mRNA therapeutics, like the Covid-19 vaccines, just recapitulate how our body’s natural mRNAs work,” Becraft explains. “Natural mRNAs last for a few days, maybe less, and they express a single protein. They have no context-dependent actions. That means wherever the mRNA is delivered, it’s only going to express a molecule for a short period of time. That’s perfect for a vaccine, but it’s much more limiting when you want to create a protein that’s actually engaging in a biological process, like activating an immune response against a tumor that could take many days or weeks.”

Technology with broad potential

Strand’s first clinical trial is targeting solid tumors like melanoma and triple-negative breast cancer. The company is also actively developing mRNA therapies that could be used to treat blood cancers.

“We’ll be expanding into new areas as we continue to de-risk the translation of the science and create new technologies,” Becraft says.

Strand plans to partner with large pharmaceutical companies as well as investors to continue developing drugs. Further down the line, the founders believe future versions of its mRNA therapies could be used to treat a broad range of diseases.

“Our thesis is: amplified expression in specific, programmed target cells for long periods of time,” Becraft says. “That approach can be utilized for [immunotherapies like] CAR T-cell therapy, both in oncology and autoimmune conditions. There are also many diseases that require cell-type specific delivery and expression of proteins in treatment, everything from kidney disease to types of liver disease. We can envision our technology being used for all of that.”

[wickedsrest-rp]

Name: Katherine “Kit” Clarke Species: Vampire (previously spawn vampire) Occupation: Unemployed Age: 74 Years Old (Looks about 36) Played By: Chayya Face Claim: Ruth Negga

"A little party never killed nobody… Oh, wait. Never mind."

TW: Terminal illness (breast cancer), drug abuse

Don’t believe the tabloids, okay, Kit Clarke grew up in a perfectly normal household just south of Hoboken, New Jersey. Just them and their mom and their dad and the both of them were doctors, if you can believe it. Brain-numbingly normal. They wanted the best for Kit and were often able to provide. When they started to show a real aptitude and love for music, they took that into account with piano lessons, voice training, and a gorgeous acoustic guitar. Overall, the Clarke household was loving, if ambitious, and as long as they got good grades, Kit was able to pursue their own interests as well. 

But they were, still, eventually, a teenager, and one with a fun-seeking edge. Growing up where they did, it wasn’t hard at all to sneak into the City. It was innocent, for the most part – exploring the city, watching the people and, of course, checking out the music venues. Any club that would let a kid so obviously underage come in was on Kit’s radar and they become a regular. And when they had open mics, well, how could they resist?

And that’s how Kit met Matty. He heard them sing in some crappy, hole-in-the-wall club that he had snuck out to and the rest is history. Or, at least, the rest is better left to be hashed out by VH1’s Behind the Music and MTV’s Where Are They Now?

Matty and Kit ran deep, quickly, and it wasn’t long before they were putting together a band. It was just smashing around, in those early days, just jamming and giggling and making dreamy-eyed plans. Kit’s parents Did Not Approve, but, hey, they were still keeping their grades up so they let it go. But then Kit told them that they were skipping out on college, that the band had actually landed some gigs and they wanted to make a real go of it. They may have had dreams of them becoming a doctor, like them, or something else stable and steady and normal, but Kit was eighteen by then and they done this to themselves in some sense. They raised Kit to be independent and ambitious and unapologetic and that’s how they ran off with the band. 

And god, it was good. It was amazing. It was more than Kit ever could have imagined, traveling the country with this band that was easily becoming a second family. Making music and playing it and having people like it. Insane. And they got to do it all with their best friend. It was cosmic shit, what they were doing and  they loved every second it (except maybe the fucking tabloids but, well, every rose, right?). It was a whirlwind boardwalk ride and through it all Kit wrote letters to their parents, sent them money even though they didn’t need it. They wrote back asking if they were okay, asking when they would be coming home next, tentatively trying to address the rumors they had read about drugs in the band.

And then Matty was turned and that sure was a trip. Kit was the one who found him, crazed and bloody and with no heartbeat in some alleyway. But just like everything else, they figured it out, together, as a band, as a family. And it turned out they all rocked through it. Diamondbacks charged on. And now they had proof they could outlast anything. 

Until Kit’s diagnosis came in.

It was triple-negative and it had spread and they could try chemotherapy but their odds weren’t good. And then they tried the chemotherapy and it was awful, they’ve never felt so sick. They stopped the treatment, wanting to go home and die in peace. Except that wasn’t the plan at all because they had, shamefully, asked Matty to turn them and he agreed. Only it all went wrong.

Forty years of nothing. Forty years of just blood and cravings and hunger and instinct and hunting. Forty years of feed, feed, feed, with only the barest brush of comfort from Matty at the edges of their consciousness, in their bond.

Coming back was excruciating. Regaining their mind, regaining control and full consciousness. It all hurts and it’s all hard, even with Matty by their side.

Character Facts:

Personality: Fun-loving, friendly, compassionate, goofy, musical, ambitious, tempestuous, avoidant, wary

Happily responds to any pronouns but prefers “they” and “she.”

A founding member of The Diamondbacks with Matty, Kit was one of the key lyricists and bassists and would often lend a hand on vocals. They can also play guitar and keyboard well, but their instrumental prowess is nowhere near Matty’s virtuoso talent. 

To the rest of the world, Kit died in 1983 from breast cancer. Only those in the band know what truly happened.

Yes, they still talk with a North Jersey accent, whadda ya gonna do aboudit?

They’ve technically not been around for the past 40 years or so there’s a lot for them to adjust to and learn. No one tell them about that other guy who’s singing in Van Halen.

[mybodyispeace]

if anyone has anything they want me to tattoo on myself to help bring awareness/etc please let me know :) this is the whole reason im doing this

[glcarissa]

Follow my Stage 4 Metastatic Breast Cancer journey on IG: @metastaticbreastcancer4

Abstract Artist with Stage 4 Breast Cancer: They say an artist becomes famous after they ...

[bhushans]

Unveiling the Power of Data: Global Breast Cancer Drug Market

The global breast cancer drug market is set for steady growth over the next decade. Valued at USD 10,733.1 million in 2023, the market is projected to reach approximately USD 12,012.1 million by 2033, with a compound annual growth rate (CAGR) of 1.1% during the forecast period.

The increasing prevalence of breast cancer and the continuous evolution of novel therapies are key factors driving this market expansion. Early detection remains crucial for the effective management and treatment of breast cancer, further bolstering the demand for advanced drug therapies.

Your Insightful Report Sample With Your Work Email: https://www.futuremarketinsights.com/reports/sample/rep-gb-1246

One of the most prevalent malignancies affecting women globally, breast cancer has a significant effect on public health. Improving patient outcomes and lowering the disease’s mortality rates depend on the creation of novel treatments as well as improvements in early detection techniques.

Breast cancer is caused by a multitude of factors, such as genetic mutations (abnormal variations), age, inheritance, lifestyle, and heredity. Researchers are looking into novel imaging modalities to assess anomalies during the early stages of the disease and trying to determine the impact of genetic changes on breast cancer.

Key Takeaways:

The global breast cancer drug market is projected to reach US$12,012.1 million by 2033, reflecting a rise from US$10,733.1 million in 2023.

This growth is expected at a moderate compound annual growth rate (CAGR) of 1.1% throughout the forecast period.

The rising prevalence of breast cancer and the development of novel therapies are key drivers for market expansion.

Competitive Landscape:

In August 2021, Pfizer Inc. and Trillium Therapeutics Inc. entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash.

In June 2022, Novartis announced new overall survival (OS) and quality of life (QoL) analyses which evaluated Kisqali® (ribociclib) plus endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced or metastatic breast cancer.

Key Companies Profiled:

F. Hoffmann-La Roche Ltd

Pfizer Inc.

AstraZeneca

Novartis International AG

Achieve Life Science

Bristol-Myers Squibb

Eisai Co. Ltd

AbbVie

Eli Lilly & Company

Celgene Corporation

Merck & Co.

Amgen Plc.

Celldex Therapeutics

Biocon Genzyme Corporation

Key Segments Covered in the Breast Cancer Drug Industry Analysis:

By Drug Class:

SERM (Selective Estrogen-Receptor Modulators)-based

Aromatase Inhibitors-based

Biologic Response Modifiers-based

Other Hormonal Therapies-based

By Distribution Channel:

Hospital Pharmacies

Pharmacies

Drug Stores

By Region:

North America

Latin America

Europe

Asia Pacific

Middle East & Africa

[marketreports-blog]

The global breast cancer drugs market in terms of revenue was estimated to be worth USD 32.93 billion in 2023 and is poised to reach USD 78.61 billion by 2033, growing at a CAGR of 9.09% from 2024 to 2033. The new research study consists of an industry trend analysis of the market.

[jasgurlifesciences]

Buy Advanced Breast Cancer Drug Palbojas 125 Mg

Palbojas 125 mg capsules, manufactured by Jasgur Life Sciences, offer new hope for cancer patients battling metastatic breast cancer. Through its innovative mechanism of action, Palbojas works to block the activity of cyclin-dependent kinases (CDKs), key enzymes involved in cell cycle regulation. By inhibiting CDKs, Palbojas effectively arrests the proliferation of cancer cells, slowing down disease progression. This medication has shown promising results in clinical trials, demonstrating prolonged progression-free survival rates and improved overall survival in patients. With its proven efficacy and tolerable safety profile, Palbojas stands as a beacon of hope for individuals facing the challenges of advanced breast cancer.

[pratiksha16]

Breast Cancer Drugs Market Size, Status and Growth Outlook 2024 to 2031

The Breast Cancer Drugs Market is a crucial segment within the pharmaceutical industry, dedicated to providing effective treatment options for individuals diagnosed with breast cancer. Breast cancer remains one of the most prevalent forms of cancer globally, with millions of new cases reported each year. The market for breast cancer drugs encompasses a wide range of therapeutic interventions, including chemotherapy, hormone therapy, targeted therapy, and immunotherapy, tailored to address the diverse molecular subtypes and stages of breast cancer.

Get PDF Sample Copy of Report:

Drivers:

One of the primary drivers of the Breast Cancer Drugs Market is the rising incidence of breast cancer worldwide. Factors such as aging populations, lifestyle changes, and increased awareness leading to early detection contribute to the growing number of breast cancer cases. Additionally, advancements in diagnostic techniques and genetic testing have improved the accuracy of breast cancer diagnosis, leading to higher demand for effective treatment options.

Restraints:

Despite the promising growth prospects, the Breast Cancer Drugs Market faces certain challenges and restraints. One of the key challenges is the high cost associated with cancer treatment, including the price of drugs and supportive care services. Access to affordable breast cancer drugs remains a significant concern, particularly in developing countries with limited healthcare resources and infrastructure. Additionally, regulatory hurdles, drug resistance, and the emergence of generic competition pose challenges to market expansion.

Challenges:

However, several factors contribute to the continued growth of the Breast Cancer Drugs Market. Ongoing research and development efforts aimed at identifying novel drug targets and therapeutic approaches drive innovation in the field. Furthermore, collaborations between pharmaceutical companies, academic institutions, and research organizations facilitate the development of new treatment modalities and combination therapies. Advances in technology, such as next-generation sequencing and liquid biopsy, also play a crucial role in guiding treatment decisions and monitoring disease progression.

Conclusion:

In conclusion, the Breast Cancer Drugs Market is characterized by continuous innovation, driven by the need to address the rising burden of breast cancer globally. While challenges such as high treatment costs and regulatory hurdles exist, ongoing research efforts, technological advancements, and collaborative initiatives are driving progress in breast cancer treatment. With a growing emphasis on personalized medicine and early detection, the market for breast cancer drugs is expected to witness significant growth in the coming years, offering hope to millions of patients worldwide.

Read the full analysis report for better understanding (description, TOC, list of tables and figures, and much more):  https://www.sanglobalresearch.com/report/breast-cancer-drugs-market/3015

Global Medical Devices Market, Report Segmentation

Medical Devices Market, By Therapy Method

Targeted

Hormonal

Medical Devices Market, By Distribution

Hospital Pharmacies

Retail Pharmacies

Others

On the basis of region

• North America

• Europe

• Asia Pacific

• South America and

• Middle East and Africa

Key Players:

The key market players operating in the Global Breast Cancer Drugs Market include

Bristol-Myers Squibb Company, Macrogenics, Inc., Celldex Therapeutics; Onyx Pharmaceuticals Inc., Genzyme Corp., F. Hoffmann-La Roche Ltd., AstraZeneca, AbbVie Inc.

Related Reports:

Hair Growth Supplements Market: https://www.sanglobalresearch.com/report/hair-growth-supplements-market/3108

Digital Therapeutics Market: https://www.sanglobalresearch.com/report/digital-therapeutics-market-/3107

Health Care Wastewater Treatment Market: https://www.sanglobalresearch.com/report/health-care-wastewater-treatment-market-/3106

Thank you for reading the report. The report can be customized as per the requirements of the clients. For further information or query about customization, please reach out to us, and we will offer you the report best suited for your needs.

About Us:

At San Global Research Report, we pride ourselves on our commitment to quality and accuracy. Our team of experienced researchers utilizes a combination of quantitative and qualitative methods to ensure that our findings are both accurate and reliable. With a strong emphasis on responsiveness, transparency, and collaboration, we work closely with our clients to understand their objectives and deliver actionable insights. Learn more about our research approach and how it can benefit your business.

Contact Us:

Address: Gera Imperium Rise, Phase 2 Hinjewadi, Pune, India

San Global Research | Web: http://www.sanglobalresearch.com

Direct Line: +91 9209275355 E-mail: hello@sanglobalresearch.com

[innonurse]

ChatGPT vs Elicit: GenAI battle in medical research

- By InnoNurse Staff -

A research team led by Professor Masaru Enomoto of Osaka Metropolitan University's Graduate School of Medicine gave identical clinical questions and literature selection criteria to two generative AIs, ChatGPT and Elicit.

Read more at Osaka Metropolitan University/EurekaALert!

///

Other recent news and insights

Soundwaves harden 3D-printed deep tissue treatments (Duke University)

Medtronic cancels its $738 million purchase of an insulin patch pump manufacturer EOFlow (Fierce Biotech)

Artificial intelligence in cancer drug development for the elderly (Impact Journals LLC/Medical Xpress)

In breast cancer screenings, AI can identify women at high risk (Karolinska Institutet/Medical Xpress)

UK: App for AI medical coaching Holly Health has raised £650,000 (UKTN)

[harmeet-saggi]

Ovarian Cancer - Cause Symptoms Diagnosis & Treatment

Ovarian cancer is a type of cancer that begins in the ovaries. The ovaries are two small, almond-shaped organs located on each side of the uterus. They are responsible for producing the eggs necessary for reproduction and for secreting the female hormones estrogen and progesterone. Ovarian cancer is the fifth most common type of cancer in women and is most often diagnosed in women over the age of 60.

[jcmarchi]

Immune action at a distance

New Post has been published on https://thedigitalinsider.com/immune-action-at-a-distance/

Immune action at a distance

For most metastatic cancer types, there are no reliably effective treatments. Therapies may slow the growth of tumors, but they will not eradicate them. Occasionally, however, treating a tumor in one location will cause untreated tumors elsewhere in the body to shrink or even regress completely — a dramatic but exceedingly rare phenomenon known as the abscopal effect.

Cancer researchers have sought methods to induce the abscopal effect by design. The abscopal effect is thought to arise when dead or damaged tumor cells release antigens that teach some types of immune cells to recognize and attack other and even distant cancer cells. Essentially, the treated tumor behaves like a personalized cancer vaccine that incites the immune system to attack metastasized tumors. The advent of cancer immunoadjuvants, which enhance and sustain the activity of tumor-targeting immune cells, has been a key to unlocking the abscopal effect, at least in the laboratory setting. 

In the clinic, success has proven more elusive. Since immunotherapies can lead to serious toxicities if administered through the bloodstream, they must be delivered directly to the tumor — often by injection. It is difficult for clinicians to target injections precisely to the tumor and impossible to confirm delivery. Once injected, immunostimulatory drugs quickly leak out of the tumor before they have had a chance to take full effect.

MIT researchers, together with colleagues from Mass General Brigham, have developed a polymer gel delivery system that could help translate the promise of the abscopal effect into the clinic. The gel, visible with a CT scanner or ultrasound, solidifies after injection, where it remains in the tumor to release drugs at a controlled rate.

In a study published in Advanced Healthcare Materials, the team delivered the immune-stimulating drug imiquimod in combination with checkpoint blockade therapy to dual-tumor mouse models of colon and breast cancer, which showed improved survival as well as tumor regression in both treated and untreated tumors.

“The field has been seeking the ‘holy grail’ of the abscopal effect for the past 15 years,” says Giovanni Traverso, a senior author of the study, Karl Van Tassel Career Development Professor in the Department of Mechanical Engineering, and a member of the Koch Institute for Integrative Cancer Research at MIT. “Now, with drug-delivery materials better adapted for the clinic, it could be within reach.”

Traverso’s co-senior author is Umar Mahmood, director of the Center for Precision Imaging and chief of the Division of Nuclear Medicine and Molecular Imaging at Massachusetts General Hospital (MGH). Avik Som, interventional and diagnostic radiology resident at MGH; Jan-Georg Rosenboom, senior postdoc in the Langer and Traverso labs at the Koch Institute; and  Eric Wehrenberg-Klee, director of the Center for Image-Guided Cancer Therapy and assistant professor at Harvard Medical School, are co-lead authors. Robert Langer, David H. Koch Institute Professor, is also an author of the study.

Defining the problem

At MGH, clinicians saw that of 18 patients that were treated with an intratumoral injection of immunotherapy either just before or after undergoing a procedure known as cryoablation, one patient with metastatic melanoma showed a sustained abscopal effect. In cryoablation, a tumor is injected with freezing gas and then thawed out, with the hope of inducing a system-wide immune response to tumors.

The observation pointed to a promising avenue for achieving the abscopal effect for more patients, but a new tool was needed to address some of the realities of intratumoral injections in the clinic. In addition to the difficulties of delivering intratumoral injections for the clinician, these treatments are costly and infeasible for patients. Because tumors do not retain immunotherapies for long, patients require repeat injections — with sedation — over several days. The clinicians looked across the river to their MIT colleagues for help.

 “My clinical colleagues came to us with this very interesting problem, so we thought, how can we address this from our own chemical engineering perspective?” says Rosenboom.

The interdisciplinary team determined that the injected material would need to be liquid at room temperature during injection, and then solidify once inside the tumor to prevent leakage. For optimal drug delivery, the gel would need to carry a high concentration of drug in a small volume and then release its payload in a controlled fashion over several days. The team planned to add an iodinated and clinically approved contrast agent to make it visible with a CT scan to help clinicians confirm they have successfully injected the material. To help smooth the path of the platform to the clinic, the gel should be known to be safe and biocompatible and the immunotherapy it transports to have proven effectiveness.

“As a radiologist, I can see tumors under CT or ultrasound, but I can’t see the drugs they are asking me to inject!” says Som. “That’s why we designed a formulation for a promising immunoadjuvant that could be image guided by both modalities. This platform should hopefully realize the immense promise of personalized cancer vaccines.”

Adds Wehrenberg-Klee, “When developing new intratumoral immunotherapies, being able to confirm delivery into tumor is a critical variable. Intratumoral immunotherapy relies on the assumption that you are delivering therapy to tumor, but our clinical experience suggests this may not always be true. If we can see what we’ve injected, we can eliminate that concern.”

“As engineers, we needed to solve the problem of how to tune a polymer formulation to achieve injectability, solidification at body temperature, prolonged drug release, and visibility — all at the same time, all while these properties affect one another,” says Rosenboom. “That took us about four years to figure out.”

A solution gels

After investigating several polymers, the researchers found that a three-part polymer called PLGA-PEG-PLGA would help them balance the several competing features required of their platform. The polymer is thermosensitive. With slight changes to its molecular weight (size), it can be adjusted to be liquid at room temperature during injection and more viscous in the warmer environment of the tumor.

The polymer is also amphiphilic, with a PEG block that is attracted to water and two PLGA blocks that repel water, so that it forms a nanoparticle around the hydrophobic drug. Its amphiphilic properties allow its drug-release behaviors to be precisely tuned: the more hydrophobic the PLGA block, the slower the release. The formulation allowed a slowed drug release over four to five days, which was a timeframe previously reported to be effective when injected daily.

A similar version of the polymer has already been studied in clinical trials for delivering a type of chemotherapy, paclitaxel. However, in this scenario, the gel would transport imiquimod, an immunotherapy already approved by the Food and Drug Administration (FDA) that is commonly used topically to treat basal cell carcinoma.

Once the gel had been tailored to meet their requirements, the team tested it in mouse models of colon and breast cancer that are usually resistant to immunotherapy. In combination with a type of immunotherapy called checkpoint blockade therapy, they used the platform to deliver imiquimod. Each mouse had two tumors of the same type, but only one tumor was treated. If both tumors regressed, then the researchers could confirm their platform could induce a system-wide immune response to tumors — the abscopal effect.

Overall, the combination of checkpoint blockade therapy and intratumorally delivered imiquimod resulted in improved survival in both colon and breast cancer models. The treatment resulted in an all-or-nothing response, with complete regression of both the treated and untreated tumors in the mice that did respond to therapy. For nonresponders, there was no regression in either tumor. The researchers also tested the combination therapy of gel-delivered imiquimod and checkpoint blockade therapy with and without cryoablation of the treated tumor and found that the two approaches gave similar results.

Because the platform is made from safe materials to deliver an already-approved drug, the team expects that the path to FDA approval will be significantly shorter than for completely novel platforms and therapies. The team is also working with industry partners to adapt the platform for treating other tumor types and to deliver other therapies.

This study was funded in part by a Philips RSNA Research Award, a Schlaeger Research Fellowship, a postdoctoral fellowship from the Ludwig Center at the Koch Institute, and grants from Boston Scientific, the MIT Deshpande Center for Technological Innovation, and the National Cancer Institute.

[healthcaredbmrnews]

Breast Cancer Drug Market Overview, Growth Analysis, Share, Opportunities, Trends and Global Forecast By 2030

Global Breast Cancer Drug  Market' the new research report adds in Data Bridge Market Research's reports database. This Research Report spread across 329 Page, 53 No of Tables, And 244 No of Figures with summarizing Top companies, with tables and figures. The Breast Cancer Drug  market research report presents a comprehensive study on production capacity, consumption, import and export for all the major regions across the world. By keeping in mind the end user's point of view, a team of researchers, forecasters, analysts and industry expert's work in-depth to formulate this Breast Cancer Drug  market research report.

The research and analysis carried out in this Breast Cancer Drug  report assists clients to forecast investment in an emerging market, expansion of market share or success of a new product. To turn complex market insights into simpler version, well established tools and techniques are used for generation of Breast Cancer Drug  report.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @

https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-breast-cancer-drug-market

The increasing prevalence of breast cancer and growing awareness and early detection have significantly improved the design and functionality of the breast cancer drug market, and have carved the way for the growth of the breast cancer drug market. The market for breast cancer drugs has been growing steadily due to several factors. Firstly, there are some technological advancements in breast cancer drug which has been a driver in the market. Additionally, there is an increasing geriatric population which also contributes to the market for breast cancer drug market.

Data Bridge Market Research analyses that the global breast cancer drug market, which was USD 10,637.42 million in 2022, would rocket up to USD 11,750.33 million by 2030, and is expected to undergo a CAGR of 1.1% during the forecast period. This indicates that the Ductal Carcinoma In Situ (DCIS) segment dominates the type segment of the breast cancer drug market owing to the advancements in technology that have led to the development of rapid and implant drugs and treatments for various use. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

The global breast cancer drug market refers to the market for pharmaceutical products specifically developed and used for treating breast cancer. It encompasses the research, development, manufacturing, and commercialization of drugs improving combat breast cancer and patient outcomes.

The market includes various types of drugs, such as chemotherapy agents, hormone therapies, targeted therapies, immunotherapies, and combination therapies. These drugs are designed to target cancer cells in the breast, inhibit their growth, prevent metastasis, and improve survival rates.

Access Full 350 Pages PDF Report @

https://www.databridgemarketresearch.com/reports/global-breast-cancer-drug-market

The Breast Cancer Drug  Market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance.

Key points covered in the report: -

The pivotal aspect considered in the global Breast Cancer Drug  Market report consists of the major competitors functioning in the global market.

The report includes profiles of companies with prominent positions in the global market.

The sales, corporate strategies and technical capabilities of key manufacturers are also mentioned in the report.

The driving factors for the growth of the global Breast Cancer Drug  Market are thoroughly explained along with in-depth descriptions of the industry end users.

The report also elucidates important application segments of the global market to readers/users.

This report performs a SWOT analysis of the market. In the final section, the report recalls the sentiments and perspectives of industry-prepared and trained experts.

The experts also evaluate the export/import policies that might propel the growth of the Global Breast Cancer Drug  Market.

The Global Breast Cancer Drug  Market report provides valuable information for policymakers, investors, stakeholders, service providers, producers, suppliers, and organizations operating in the industry and looking to purchase this research document.

Table of Content:

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Global Breast Cancer Drug  Market Landscape

Part 04: Global Breast Cancer Drug  Market Sizing

Part 05: Global Breast Cancer Drug  Market by Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

For More Insights Get Detailed TOC @

https://www.databridgemarketresearch.com/toc/?dbmr=global-breast-cancer-drug-market

The investment made in the study would provide you access to information such as:

Breast Cancer Drug  Market [Global – Broken-down into regions]

Regional level split [North America, Europe, Asia Pacific, South America, Middle East & Africa]

Country-wise Market Size Split [of important countries with major market share]

Market Share and Revenue/Sales by leading players

Market Trends – Emerging Technologies/products/start-ups, PESTEL Analysis, SWOT Analysis, Porter’s Five Forces, etc.

Market Size

Market Size by application/industry verticals

Market Projections/Forecast

Browse Trending Reports:

 Global Hospital Asset Management Market Size, Share and Opportunities https://www.databridgemarketresearch.com/reports/global hospital asset management market

 Global Hpv Testing Pap Test Market Size, Share and Opportunities https://www.databridgemarketresearch.com/reports/global hpv testing pap test market

 Global Interoperable Healthcare Solutions Market Size, Share and Opportunities https://www.databridgemarketresearch.com/reports/global interoperable healthcare solutions market

 Global Lithotripsy Devices Market Size, Share and Opportunities https://www.databridgemarketresearch.com/reports/global lithotripsy devices market

 Global Long Term Care Software Market Size, Share and Opportunities https://www.databridgemarketresearch.com/reports/global long term care software market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: corporatesales@databridgemarketresearch.com

[bhushans]

Global Breast Cancer Drug market: A Deep Dive into Key Drivers and Trends

The global Breast Cancer Drug market. According to a recent analysis, the market size is projected to be worth US$ 10,733.1 million in 2023. Between 2023 and 2033, the total demand for breast cancer medications is expected to expand at a Compound Annual Growth Rate (CAGR) of 1.1%, reaching approximately US$ 12,012.1 million by that time.

Breast cancer remains a significant healthcare challenge globally, with the disease's rising prevalence driving the demand for innovative treatments. Effective care of breast cancer necessitates early diagnosis and access to advanced therapies, highlighting the importance of continued innovation and development in the breast cancer drug market.

Inform Decisions With a Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-1246

Addressing Breast Cancer: A Market Focused on Innovation and Early Detection

The global breast cancer drug market is experiencing steady growth, driven by the continuous need for effective treatment options and the ongoing battle against this prevalent disease. Early detection remains a critical factor in managing breast cancer effectively.

Multiple Factors Shape Market Landscape:

Although growth is projected to be modest, several factors are influencing the breast cancer drug market:

Rising Prevalence: Unfortunately, the number of breast cancer diagnoses is expected to continue rising globally. This creates a larger patient population in need of treatment.

Novel Therapies: The development of innovative therapies, such as targeted drugs and immunotherapies, offers new treatment options and hope for improved patient outcomes.

Focus on Early Detection: Increased awareness campaigns and improved diagnostic tools contribute to earlier detection, allowing for more effective treatment interventions.

Key Takeaways:

The global breast cancer drug market is projected to reach US$12,012.1 million by 2033, reflecting a rise from US$10,733.1 million in 2023.

This growth is expected at a moderate compound annual growth rate (CAGR) of 1.1% throughout the forecast period.

The rising prevalence of breast cancer and the development of novel therapies are key drivers for market expansion.

Competitive Landscape:

In August 2021, Pfizer Inc. and Trillium Therapeutics Inc. entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash.

In June 2022, Novartis announced new overall survival (OS) and quality of life (QoL) analyses which evaluated Kisqali® (ribociclib) plus endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced or metastatic breast cancer.

Key Companies Profiled:

F. Hoffmann-La Roche Ltd

Pfizer Inc.

AstraZeneca

Novartis International AG

Achieve Life Science

Bristol-Myers Squibb

Eisai Co. Ltd

AbbVie

Eli Lilly & Company

Celgene Corporation

Merck & Co.

Amgen Plc.

Celldex Therapeutics

Biocon Genzyme Corporation

Key Segments Covered in the Breast Cancer Drug Industry Analysis:

By Drug Class:

SERM (Selective Estrogen-Receptor Modulators)-based

Aromatase Inhibitors-based

Biologic Response Modifiers-based

Other Hormonal Therapies-based

By Distribution Channel:

Hospital Pharmacies

Pharmacies

Drug Stores

By Region:

North America

Latin America

Europe

Asia Pacific

Middle East & Africa

[icarusredwings]

Thinking about how adaptive Logan is and how he can quite physically tell the difference between people even if they look identical by chemical scent alone.

With being around Wade so much, do you ever think he just gets a whiff of a stranger and turns to Wade like "Hey.. I think... they have cancer."

For a second, he thinks he's mocking him, but the look of seriousness on his face makes him frown and is like, "Holy shit.. Wait, you can smell cancer?? What are you like a cancer dog?"

"Shut up, im serious."

"Wait for real? Are you sure it's just not old lady perfume?"

"I-i think so...?? ....Should.... should I tell her? Oh man.. how do I tell a stranger that they have a horrible disease?"

Wades is about to make a joke but decides not to, remembering how life ruining it was to sit there and stare at vanessa as the doctor sounded like charlie browns parents.

"... where is it?"

"I don't know. I just.. I think maybe in the top bit? What would I even say? Hey, im a super smelling mutant, and I think you have breast cancer."

".. yes."

"Really?"

"You have to tell her... She'll get scared if I tell her."

So he does. Awkwardly comes up to this woman and explains some bullshit how he was 'born with super smells' and how he believes she might have some form of cancer. That- if she acts early enough- they might be able to beat it.

For some reason, the woman cries and tells him how this would make sense because shes felt sick the last couple of weeks and had no clue why. That she'll make an appointment as soon as possible. "Thank you."

Logan is left with a warm feeling in his chest, and smiles lopsided as she goes about her day.

Wade is left feeling both envious and proud at the same time. No, there wasn't a wolverine to warn him of his sickness, but this doesn't mean they can't help others.

So from then on, sniffing becomes an automatic reflex, sniffing all the kids at the mansion, class by class, every teacher, anyone he possibly can. It breaks his heart when he finds one. Everyone holds their breath, hoping he doesn't, but sometimes he does. He always cries afterward.

You know those drug/ weapon dog searches that schools sometimes have? Yeah that's bassically what happens except he pops a head in, says a quick "clear" and goes to the next room. Its real terrifying when he actually comes into the room and starts walking around.

This being said. If you're sneaking drugs into the school? You better be tight with Mr. Howlett, or he's turning you in to Mrs. Munroe.